Development of anti-hGH antibodies during therapy with authentic human growth hormone.
Children treated with authentic human growth hormone (Genotropin) in clinical trials between 1985 and 1989 were tested for the presence of anti-hGH antibodies. The incidence of antibodies after 12 months of treatment was 4/373 (1.1%). Mean binding capacity was 0.07 mg/l. The results suggest that Genotropin has low immunogenicity.
Lundin
K
K
Kabi Pharmacia Peptide Hormones, Stockholm, Sweden.
Berger
L
L
Blomberg
F
F
Wilton
P
P
D000906:Antibodies / Q000097:blood*; D002648:Child; D005260:Female; D006130:Growth Disorders / Q000188:drug therapy; D013006:Growth Hormone / Q000276:immunology* / Q000627:therapeutic use; D006801:Humans; D011994:Recombinant Proteins / Q000276:immunology / Q000627:therapeutic use; D014424:Turner Syndrome / Q000188:drug therapy
D000906:Antibodies; D011994:Recombinant Proteins; D013006:Growth Hormone